FDA Approves New Pancreatic Cancer Drug Rasonque

Why it matters locally: New York residents battling metastatic pancreatic cancer may soon have access to a new treatment option following the FDA's accelerated approval of Rasonque, a RAS inhibitor.

WASHINGTON – The U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib) today, introducing a new treatment for metastatic pancreatic cancer. Rasonque functions as a RAS inhibitor, targeting the most common form of the disease. Regulators made the approval several months ahead of their projected schedule. The decision makes Rasonque available to patients with advanced pancreatic cancer.